Citius Oncology Inc (CTOR)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$0.86+8.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · CTOR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 4 industry peers · Company calendar date is not available
CTOR — General Counsel transition
Dated 2026-08-12
Director — Jonathan Peri: The filing describes the appointment of a new independent director to fill an expanded board seat, which is a standard governance action and not a departure of senior management.
Why it matters: Hitting this target shows good market acceptance and success.
Supportive ifBy December 2026, 100 institutions are prescribing LYMPHIR. This shows strong adoption.
Worry ifFewer than 80 institutions are prescribing LYMPHIR by year-end. This shows slow uptake.
Why it matters: A fully deployed team would enhance market reach and support LYMPHIR's sales growth.
Supportive ifThe company confirms that the full commercial team is operational by the end of Q3.
Worry ifThe commercial team is not complete. This limits sales efforts and market reach.
Why it matters: A rise in vial orders shows strong market acceptance and demand for LYMPHIR.
Supportive ifIn Q3 2026, orders for vials are over 1,000. This shows strong demand.
Worry ifVial orders are under 1,000. This shows weak market acceptance.
Why it matters: More independent board members can help with governance and oversight. This may help the company long-term.
Supportive ifAt least one more independent director is appointed to the board.
Worry ifNo new independent directors are appointed to the board in the next quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$241 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $871 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,571 loss on $10,000 · 75.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Following rules helps Citius keep its listing. It also builds trust with investors.
Worry ifCitius shows it meets Nasdaq's listing rules.
Less concerning ifThere is ongoing non-compliance with Nasdaq rules without a clear plan.
Why it matters: Surpassing this revenue mark would indicate strong sales growth for LYMPHIR.
Supportive ifNet revenue for Q3 2026 exceeds $10 million, showing strong market traction.
Worry ifNet revenue for Q3 2026 is below $7 million, suggesting weak demand.
Why it matters: New data from trials could boost LYMPHIR's market potential. Good results may attract more interest and increase sales.
Watch forThere are good updates from Phase 1 studies of LYMPHIR. These studies use combination therapies.
Also watch forNegative updates or delays in the clinical trials of LYMPHIR.
Why it matters: A full sales team is key for LYMPHIR's market growth.
Supportive ifCitius announces the full deployment of the commercial sales team by July 2026.
Worry ifDelay in deploying the sales team beyond mid-summer 2026.
Why it matters: Starting this study shows progress in development. It could boost investor trust in LYMPHIR.
Supportive ifAnnouncement of a Phase 2 expansion study for LYMPHIR.
Worry ifNo announcement of the Phase 2 expansion study by the end of 2026.
Why it matters: Full payer coverage shows strong market acceptance. This can lead to more sales.
Supportive ifThere is 100% payer coverage for LYMPHIR. There are no reimbursement denials.
Worry ifReports of reimbursement denials or big payer coverage problems are a concern.
Why it matters: More revenue shows strong market acceptance. This helps Citius Oncology grow.
Supportive ifRevenue from LYMPHIR exceeds $1.5 million in Q3.
Worry ifRevenue from LYMPHIR falls below $1.5 million in Q3.